Business Wire

Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial

Share

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has entered into a research agreement with Invectys, a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. Under the terms of the agreement, Personalis will provide comprehensive tumor immunogenomics capabilities to facilitate biomarker discovery in chronic lymphocytic leukemia (CLL) patients enrolled in a Phase II clinical trial assessing the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptase (hTERT) protein, as monotherapy or in combination with ibrutinib.

“Personalis is known for their innovative and expansive cancer immunogenomics expertise, and we’re delighted to partner with them on this project to evaluate biomarker signatures in responders and non-responders to our leading cancer vaccine candidate, INVAC-1,” said Pierre Langlade Demoyen, CEO of Invectys. “INVAC-1 has the potential to become a key component of combination therapy approaches for the treatment of various solid and hematologic cancer types. Our work with Personalis will help us to determine which patients are most likely to respond favorably to these novel treatment regimens.”

Invectys is now enrolling CLL patients in this Phase II, open-label, single-arm trial consisting of two patient groups: 45 patients receiving INVAC-1 as monotherapy and an additional 45 patients receiving INVAC-1 in combination with ibrutinib, a Bruton's Tyrosine Kinase inhibitor. The primary goal of the study is to achieve minimal residual disease negativity in both groups. The trial is being conducted at the MD Anderson Cancer Center in Houston, Texas. For more information, please visit clinicaltrials.gov identifier NCT03265717.

“Invectys has built an exciting pipeline of novel, next-generation immunotherapies, and we’re thrilled to help drive their lead program forward,” said John West, CEO of Personalis. “Having already established ourselves as a leader in comprehensive tumor immunogenomic profiling and biomarker discovery for solid tumor indications, we’ve seen increasing use of our capabilities for biomarker evaluation in hematologic cancer types. This bodes well as we continue to rollout and onboard customers for our newly-launched, universal cancer immunogenomics platform, ImmunoID NeXT™.”

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

About Invectys

Founded in 2010 at the Pasteur Institute in Paris, Invectys SA is a biopharmaceutical company focused on the development of innovative immuno-oncology treatments. Invectys has raised €38 million. The company has developed a broad pipeline including one platform designed to provide low-cost, easy-to-administer cancer therapies, alone or in combination with other treatments such as immune checkpoint antibodies. Invectys products aim to enlist and restore natural antitumor efficacy in cancer patients.

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the development as INVAC-1 as a treatment for solid and hematologic cancer types; and the use and adoption of ImmunoID NeXT™. These forward-looking statements are subject to risks and uncertainties, including those discussed in Personalis’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

Contact information

Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678

Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

Media Contact for Invectys:
Gilles Petitot
gilles.petitot@acorelis.com
www.invectys.com
+33-620-276-594

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ISACA Combines EuroCACS and CSX Conferences for the First Time in ISACA’s 50th Anniversary Year17.9.2019 14:15:00 CESTPress release

Digital transformation and emerging technologies are the focus of ISACA’s combined EuroCACS/Cybersecurity Nexus (CSX) conference in Geneva, Switzerland, from 16-18 October 2019, as ISACA continues celebrating its 50th anniversary year. Sessions focused on DevOps, Agile, cryptocurrency, mobile payments, the Internet of Things (IoT), and other hot topics will bring together business technology professionals who lead information systems audit, risk, governance and security functions at their enterprises. Keynote speaker Anders Sorman-Nillson, a global futurist and innovation strategist, will open EuroCACS/CSX, and entrepreneur Jon Duschinsky, who was voted the second-most influential communicator in social innovation, will deliver the closing keynote. Also planned is a general-session panel to mark ISACA’s 50th anniversary in 2019 that features industry experts in innovation and a concurrent general session on “The Weaponisation of the IoT.” Attendees can advance their skills across techn

Andersen Global Expands in Rwanda17.9.2019 13:30:00 CESTPress release

Andersen Global announced today a collaboration agreement with MRB Attorneys in Rwanda. The addition of the Kigali-based firm marks the 16th country with a presence in Africa for Andersen Global. MRB Attorneys was founded in 2013 by the firm’s five partners, who all have extensive experience in private and public legal consultancy services. Today, MRB’s eleven attorneys advise clients in corporate and commercial law, dispute resolution, energy and infrastructure, and government business and policy, with a heavy emphasis on banking and investment issues. They represent a broad clientele of banks, private and public companies, international organizations, and government agencies. “Andersen Global’s reputation of stewardship and transparency lines up well with what our clients value and have come to expect from us. The synergetic collaboration will be beneficial for our clients and our people,” said Emmanuel Butare, MRB Attorneys’ Managing Partner. “We are excited to work with like-minded

Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment17.9.2019 13:15:00 CESTPress release

There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devices suppliers. Cancer treatment is one of medical specialties that Taiwan gains recognition in Asia. The focal point now goes to proton therapy, which is proven to be a painless way to deliver radiation dose in targeted tumours precisely and maintains side effects happening in the minimum level. Proton therapy key players race for Asia markets Despite proton therapy indicating a promising alternative for cancer treatments, it is far from close to a mainstream service that can be found in medical institutes. As per PTCOG statistics, there are 82 medical institutes to date having the therapy on offer, with one in operation and 9 to go in Taiwan- the highest density as opposed to the rest of the world. Chang Gung Memorial Hospital launched the service in 2015, followed closely by its peers inc

CE China 2019: The International Brand Show for Consumer and Home Electronics17.9.2019 13:13:00 CESTPress release

For the first time, CE China - a global IFA event - is held from 19 to 21 September 2019 in Guangzhou, the heart of China's trade and manufacturing business. The new date in September is perfect for preparation of Singles Day and end of year business in Asia. CE China provides an ideal platform and comprehensive services for consumer electronics and home appliance brands. The show has successfully established partnerships with leading global retailer chains such as Suning and Alibaba’s Tmall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005728/en/ Autonomous driving and new mobility at CE China 2019 CE China 2019 includes Connected Driving and New Energy Vehicles section in its spectrum tackling the trend of autonomous driving. Today, intelligent interconnection is not only a major trend in household appliances and electronic consumer goods, but also key to the automotive industry – bringing consumer electronics, hou

Zscaler Extends Edge Compute, Now Operating in Over 150 Data Centers17.9.2019 13:00:00 CESTPress release

Zscaler, Inc., the leader in cloud security, today announced the Zscaler™ platform is now distributed across over 150 data centers, with the company’s latest data center opening in Val-du-Roi, Normandy, France. The expansion is part of the company’s ongoing mission to provide enterprise users with fast, secure, reliable access to applications and services regardless of location, empowering enterprises to accelerate their cloud adoption, securely. Built on the Zscaler multi-tenant cloud architecture, the Zscaler platform unifies secure internet gateway services, cloud sandbox, next-generation cloud firewall, data loss prevention, SSL decryption, bandwidth control, and more, with simplified policy management and reporting. It is now distributed across more than 150 data centers on six continents, which enables users to access the internet and cloud services securely from any device, any location, and over any network. “The physical footprint and end-to-end control of the network, infrast

Quake Global Launches Global LTE as the Latest Innovation for Our Best-Selling Products, QPRO™ and Q4000™17.9.2019 13:00:00 CESTPress release

Quake Global, Inc. is excited to announce the availability of global LTE in our best-selling products, QPRO™ and Q4000™, which both come with bi-directional and dual-mode communication protocols over global satellite and cellular networks. Q4000 and QPRO are now available to our customers across the globe featuring the latest LTE communication technology, Cat M1/NB-IoT. This technology is designed to support M2M markets with a special focus on lower data costs for IoT data-driven applications. LTE is ideal for our customers who have equipment spanning significant geographic areas. The robust hardware housing and platform are designed to withstand extreme weather conditions, challenging work environments and are built to last. “At Quake, we continually strive to bring the most advanced telecommunication technology to our customers to ensure connectivity to assets in every part of the world,” said Polina Braunstein, CEO and President of Quake Global. Quake’s QRO and Q4000 family of produ